New hope for tough leukemia: drug targets resistant cancer cells
NCT ID NCT07471841
First seen Mar 15, 2026 · Last updated May 23, 2026 · Updated 9 times
Summary
This study tests a drug called olutasidenib in 25 adults with a specific genetic form of acute myeloid leukemia (IDH1 mutated) that has returned or not responded to treatment, especially after the drug venetoclax stopped working. Participants take olutasidenib pills twice daily for 28-day cycles, and may add another drug (azacitidine) after 3 cycles if needed. The goal is to see if the drug can shrink or clear the leukemia from the bone marrow and restore normal blood counts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDH1 MUTATION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Atrium Health Wake Forest Baptist Medical Center
Winston-Salem, North Carolina, 27157, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.